<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="31941">Oxaliplatin</z:chebi> in combination with a fluoropyrimide is a treatment option for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients in the adjuvant and metastatic settings </plain></SENT>
<SENT sid="1" pm="."><plain>Very few hematological emergencies have been reported associated with <z:chebi fb="0" ids="31941">Oxaliplatin</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>These include <z:hpo ids='HP_0001890'>autoimmune hemolytic anemia</z:hpo>, <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> and <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>We present a case report of a patient who developed <z:hpo ids='HP_0000790'>hematuria</z:hpo> and <z:hpo ids='HP_0005521'>disseminated intravascular coagulation</z:hpo> while receiving the second cycle of FOLFOX and bevacizumab for metastatic <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
</text></document>